This course examines the human right to health in the context of persistent unequal access to pharmaceutical innovations. Students will study key provisions of leading human rights and intellectual property (IP) treaties that frame the global debate on access to medicines and that influence government policies regarding public health. Using the Covid-19 pandemic as a case study, students in the course will learn about new forms of legal protection available to the pharmaceutical industry, current controversies regarding patent waivers for vaccine patents, challenges affecting the development of drugs for rare diseases, and other considerations regarding equitable access to medicines/vaccines. Finally, students will study international political and economic considerations that inform the debate on global public health, with a focus on the role of the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS).
Who Should Attend?
- Attorneys wishing to stay current on relevant legal issues including those wishing to earn Continuing Legal Education (CLE) credits
- Individuals interested in justice across the spectrum of society
- Advocates for change
NotesThis course is a non-credit offering of LAW 546G available for 2 CLE credits.
Applies Towards the Following Certificates or Series
- William S. Richardson School of Law - J Term : 2022 J-Term